首页 Fate Therapeutics(usFATE)-基本信息

Fate Therapeutics(usFATE)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:78.32

最高价:80.8

成交量:778625.0

昨收价:79.01

最低价:76.17

最新价:77.99

行情图标
概要信息

英文名称:Fate Therapeutics


简介:Fate Therapeutics, Inc.于2007年4月27日在特拉华州合并,是一家临床分期生物制药公司,致力于成体干细胞治疗调节器的探索与开发,治疗罕见疾病,包括一些恶性血液病、溶酶体贮积症和肌肉营养不良


电话:1-858-8751800


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Fate Therapeutics免疫肿瘤学候选产品包括:1、FATE-NK100,一种自然杀伤(NK)细胞癌免疫疗法,由自适应记忆NK细胞组成。2、FT500,诱导多能干细胞(iPSC)衍生的NK细胞产物候选物,用于治疗晚期实体瘤。3、FT516,工程化的iPSC衍生的NK细胞产物候选物,用于治疗血液/实体肿瘤。4、FT819,工程化嵌合抗原受体19 iPSC衍生的T细胞产物候选物,用于血液/实体肿瘤。Fate Therapeutics公司的免疫调节候选产品包括:1、ProTmune,一种研究性程序性细胞免疫疗法,用作下一代同种异体造血细胞移植细胞移植物。2、ToleraCyte,用于治疗自身免疫和炎症性疾病。3、FT300 iPSC,衍生的髓源抑制细胞产物候选物,用于治疗自身免疫疾病。Fate Therapeutics, Inc.与Memorial Sloan Kettering癌症中心签订了研究合作和许可协议,以开发现成的工程T细胞产品候选药物;与加州大学圣地亚哥分校的研究合作伙伴关系,开发嵌合抗原受体靶向自然杀伤细胞癌免疫疗法。Fate Therapeutics还与Juno Therapeutics签署了战略研究合作和许可协议,以确定增强T细胞功能的小分子调节剂;与ONO Pharmaceutical Co., Ltd.签订合作协议,开发和商业化两种现成的CAR-T细胞产品。

交易日期 交易人 职位 类型 交易份额 价格
2016-11-22 Coughlin (Timothy P) Director Buy 56390 2.66
2016-11-22 Rastetter (William H) Director Buy 375939 2.66
2016-11-22 Storgard (Chris M. M.D.) Officer Buy 37593 2.66
2016-08-22 Wolchko (J Scott) Chief Executive Officer Buy 2570 1.37
2016-05-15 Storgard (Chris M. M.D.) Officer Buy 9090 --
2016-01-17 Wolchko (J Scott) Chief Executive Officer Buy 3798 1.37
2016-01-17 Wolchko (J Scott) Chief Executive Officer Buy 3702 1.63
2016-01-11 Wolchko (J Scott) Chief Executive Officer Buy 10956 --
2016-01-07 Tahl (Cindy J.D.) General Counsel Buy 6633 --
2016-01-07 Abbot (Stewart Ph.D.) Officer Buy 3863 --
2016-01-07 Shoemaker Daniel D Officer Buy 9388 --
2015-10-14 Tahl (Cindy J.D.) General Counsel Buy 40000 --
2015-10-14 Shoemaker Daniel D Officer Buy 66000 --
2015-10-14 Abbot (Stewart Ph.D.) Officer Buy 40000 --
2015-10-14 Wolchko (J Scott) Chief Operating Officer Buy 86250 --

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
SSGA Funds Management Inc 1293310 1.98% 24926 1.97% 2019-07-31
BlackRock Fund Advisors 2776655 4.26% -130309 -4.48% 2019-07-31
Franklin Advisers, Inc. 3203021 4.91% -41685 -1.28% 2019-03-31
Franklin Resources Inc 3203021 4.91% -41685 -1.28% 2019-03-31
Fidelity Management & Research Company 4281791 6.57% -1413158 -24.81% 2019-07-31
BlackRock Inc 5191274 7.96% 159491 3.17% 2019-03-31
Fidelity Management and Research Company 7048702 10.81% -331600 -4.49% 2019-03-31
FMR Inc 7048702 10.81% -331600 -4.49% 2019-03-31
Redmile Group, LLC 10359666 15.89% -216697 -2.05% 2019-03-31
Vanguard Group Inc 2721844 4.18% 179854 7.08% 2019-03-31
State Street Corporation 2596179 3.98% 562591 27.66% 2019-03-31
Casdin Capital, LLC 2550000 3.91% -- -- 2019-03-31
Vanguard Investments Australia Ltd 1394488 2.14% -72 -0.01% 2019-07-31
Polaris Venture Management Co. V,LLC 1472853 2.26% -350333 -19.22% 2019-03-31
Millennium Management LLC 1606254 2.46% 1018614 173.34% 2019-03-31
Deerfield Management Co 1702897 2.61% 48032 2.90% 2019-03-31
Artal Group S A 1800000 2.76% -350000 -16.28% 2019-03-31
Victory Capital Management Inc. 1844290 2.83% 582010 46.11% 2019-07-31
Fidelity Management Trust Co 2102092 3.22% -- -- 2019-07-31
Farallon Capital Management, L.L.C. 2500000 3.84% 300000 13.64% 2019-03-31
Partner Fund Management LP 1281536 1.97% -189464 -12.88% 2019-03-31
Fidelity SelectCo, LLC 1342856 2.06% -145502 -9.78% 2019-06-30
BlackRock Asset Management Canada Ltd 1426990 2.19% 362 0.03% 2019-05-31
Geode Capital Management, LLC 1404358 2.15% 889106 172.56% 2018-12-31
Westfield Capital Management Company, LP 1104305 1.71% 272235 32.72% 2018-12-31
Aquilo Capital Management, LLC 984596 1.53% 404367 69.69% 2018-09-30
T. Rowe Price Associates, Inc. 813195 1.26% 24099 3.05% 2018-09-30
BlackRock Institutional Trust Company NA 1283467 1.99% 169385 15.20% 2018-06-30
683 Capital Management LLC 744011 1.15% -249700 -25.13% 2018-06-30
Morgan Stanley & Co Inc 364744 0.68% 138793 61.43% 2018-06-30
J.P. Morgan Investment Management Inc 414050 0.78% 16650 4.19% 2018-06-30
Northern Trust Investments N A 570883 1.07% 73964 14.88% 2018-06-30
Venrock Management V LLC 2473187 4.70% 241629 10.83% 2017-12-31
Venrock Partners Management V LLC 2473187 4.70% 2283989 1207.20% 2017-12-31
VEF Management V LLC 2473187 4.70% 2420756 4617.03% 2017-12-31
State Street Corp 1993912 3.74% 1206749 153.30% 2018-06-30
Franklin Advisers Inc 5530749 10.36% -318030 -5.44% 2018-06-30
Invesco PowerShares Capital Mgmt LLC 417824 0.78% -- -- 2018-09-04
Columbus Circle Investors 259213 0.49% 36655 16.47% 2018-06-30
Harbor Capital Advisors Inc 301740 0.57% 301740 -- 2018-06-30
EAM Investors 279161 0.53% 279161 -- 2018-03-31
RS Investment Management Co. LLC 213720 0.40% -30940 -12.65% 2018-06-30
Endurant Capital Management LP 556679 1.06% 283979 104.14% 2017-12-31
Alyeska Investment Group, L.P. 300000 0.57% 300000 -- 2017-12-31
J. Goldman & Co LP 209000 0.40% 209000 -- 2017-12-31
Bridgeway Capital Management, Inc 256000 0.49% -- -- 2017-12-31
Wells Fargo Advisors, LLC 270785 0.51% 40856 17.77% 2017-12-31
Neuberger Berman LLC 173250 0.33% 40250 30.26% 2017-12-31
Neuberger Berman Investment Advisers LLC 133250 0.25% -40000 -23.09% 2018-01-31
Renaissance Technologies Corp 145200 0.28% -74700 -33.97% 2017-12-31
EcoR1 Capital, LLC 2262678 5.46% -274348 -10.81% 2017-09-30
Northern Trust Asset Management 95817 0.23% 884 0.93% 2018-01-31
Bvf Inc 3759398 11.01% 3759398 -- 2016-11-21
Kingdon Capital Management LLC 387294 0.93% -763653 -66.35% 2017-09-30
Telemetry Investments, L.L.C. 160000 0.39% -65700 -29.11% 2017-09-30
Goldman, Sachs & Co. 126226 0.30% 14451 12.93% 2017-09-30
ARCH Venture Partners 2473188 8.56% -- -- 2016-08-09
Board of Ttees Leland Stanford Jr Univ 291067 0.85% -- -- 2016-09-30
Lombard Odier Asset Management USA Corp 246126 0.72% -10300 -4.02% 2016-09-30
Belmont Global Advisors Inc 150000 0.44% -250000 -62.50% 2016-09-30
Jacobs Levy Equity Management, Inc. 124472 0.36% -54175 -30.33% 2016-09-30
Mellon Capital Management Corporation 39713 0.12% -3703 -8.53% 2016-09-30
ARCH Venture Fund VI L.P. 2473188 3.00% 12242281 0.10% 1999-11-30
Entities affiliated with Venrock Associates 2473187 3.00% 12242276 0.10% 1999-11-30
Amir Nashat, Sc.D 2473186 3.00% 12242271 0.10% 1999-11-30
Kingdon Capital Management, L.L.C 1554175 3.00% 7693166 0.10% 1999-11-30
Entities affiliated with OVP Venture Partners 1499467 3.00% 7422362 0.10% 1999-11-30
Wellington Management Group LLC 1420928 3.00% 7033594 0.10% 1999-11-30
FMR LLC 3084373 3.00% 15267646 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
T. Rowe Price New Horizons Fund 297500 0.46% -1000 -0.34% 2019-06-30
Fidelity Growth Company Commingled Pool 2102092 3.22% -- -- 2019-06-30
Victory RS Small Cap Growth Fund 1469710 2.25% 537120 57.59% 2019-06-30
Vanguard Total Stock Market Index Fund 1382070 2.12% -- -- 2019-06-30
SPDR 1217566 1.87% 23826 2.00% 2019-07-31
iShares Russell 2000 ETF 1161014 1.78% 21934 1.93% 2019-07-30
Franklin Biotechnology Discovery Fund 1116146 1.71% -36123 -3.13% 2019-06-30
Vanguard Extended Market Index Fund 837786 1.29% 2326 0.28% 2019-06-30
Fidelity 731373 1.12% -15500 -2.08% 2019-06-30
T. Rowe Price Health Sciences Fund 654418 1.00% -4200 -0.64% 2019-06-30
Westfield Capital Mgt Sm-Cap Gr Eq-UBS 328160 0.50% -23610 -6.71% 2019-06-30
Harbor Small Cap Growth Fund 328160 0.50% -23610 -6.71% 2019-06-30
PGIM Jennison Health Sciences Fund 364174 0.56% -- -- 2019-06-30
iShares Russell 2000 Growth ETF 479885 0.74% 5703 1.20% 2019-07-30
Columbia Acorn Fund 490151 0.75% 490151 -- 2019-06-30
UBS (Lux) EF Biotech (USD) 498528 0.76% -- -- 2019-04-30
iShares Nasdaq Biotechnology ETF 643487 0.99% 6670 1.05% 2019-07-30
Invesco DWA Healthcare Momentum ETF 364437 0.56% -- -- 2018-09-30
iShares US Small Cap ETF (CAD-Hedged) 1233908 1.89% -2070 -0.17% 2019-05-30
Federated MDT Small Cap Growth Fund 290606 0.45% 57305 24.56% 2019-03-31
State Street Russell Small/Mid Cap 266529 0.41% 15400 6.13% 2019-03-31
NT R2000 Growth Index Fund - Non-Lending 265195 0.41% 4647 1.78% 2019-03-31
State Street Russell Small Cap 250142 0.38% 5493 2.25% 2019-02-28
JPMorgan Small Cap Value Fund 282600 0.44% -- -- 2019-01-31
iShares Russell 2000 Value ETF 408913 0.63% -675 -0.16% 2018-06-21
Victory RS Science and Technology Fund 198400 0.31% -41450 -17.28% 2018-12-31
iShares Micro-Cap ETF 155154 0.24% -- -- 2018-12-31
Federated Kaufmann Fund 243300 0.38% 243300 -- 2018-09-30
ALPS Medical Breakthroughs ETF 149103 0.23% -- -- 2018-12-28
Bayview US Bio Venture MF 259100 0.40% 259100 -- 2018-02-09
Loncar Cancer Immunotherapy ETF 181722 0.28% -- -- 2018-11-30
Bridgeway Ultra Small Company Market Fd 180000 0.28% -- -- 2018-03-31
Fidelity Advisor 313896 0.59% -234608 -42.77% 2018-07-31
JPMorgan Small Cap Value A 276900 0.52% -8400 -2.94% 2018-07-31
RS Technology A 213720 0.40% -30940 -12.65% 2018-06-30
PowerShares DWA SmallCap Momentum ETF 183021 0.31% -- -- 2018-09-13
iShares Micro-Cap 133667 0.23% -- -- 2018-09-12
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 122719 0.23% -93 -0.08% 2018-07-31
Fidelity Spartan 101401 0.19% 26039 34.55% 2018-04-30
PowerShares DWA Healthcare Momentum ETF 273334 0.47% -- -- 2018-09-13
Harbor Small Cap Growth Instl 301740 0.57% 301740 -- 2018-06-30
Vanguard Extended Market Idx Inv 576988 1.08% -- -- 2018-07-31
iShares Russell 2000 Growth 472511 0.81% -456 -0.10% 2018-09-12
Vanguard Total Stock Mkt Idx 1180892 2.21% -- -- 2018-07-31
Franklin Biotechnology Discovery A 2085207 3.91% -- -- 2018-07-31
Bridgeway Ultra-Small Company Market 180000 0.34% -- -- 2018-03-31
Schwab Small Cap Index 93300 0.17% -- -- 2018-06-30
Neuberger Berman Small Cap Growth Inv 120430 0.23% -- -- 2018-05-31
Vanguard Health Care ETF 91863 0.17% 91863 -- 2018-05-31
iShares Russell 2000 Value 408913 0.92% -675 -0.16% 2018-06-21
Active Port 88364 0.17% 88364 -- 2018-03-31
Dreyfus Select Managers Small Cap Gr A 78931 0.15% 78931 -- 2018-03-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 61555 0.12% -- -- 2018-02-28
CREF Stock R1 62593 0.12% -4348 -6.50% 2018-02-28
AXA 2000 Managed Volatility K 55122 0.10% -- -- 2018-01-31
VALIC Company I Health Sciences 59700 0.11% 32376 118.49% 2018-01-31
VALIC Company I Small Cap 70000 0.13% -- -- 2017-12-31
TIAA-CREF Small-Cap Blend Idx Inst 42819 0.10% -- -- 2018-01-31
Nuveen Small Cap Growth Opp A 39378 0.09% 39378 -- 2018-01-31
BlackRock Russell 2000 54099 0.13% 2962 5.79% 2017-12-31
State Street Russell Small/Mid Cap Idx Fd Cl I 97729 0.24% 97729 -- 2017-06-30
AXA/Lord Abbett Micro Cap K 4596 0.01% -- -- 2016-11-30
iShares Core S&P Total US Stock Mkt 5853 0.01% -- -- 2017-02-07
Wilshire Micro-Cap ETF 6252 0.02% -- -- 2017-02-08
The Vanguard Total Stock Market Index 7500 0.02% -- -- 2016-12-31
Vanguard Balanced Index Inv 7800 0.02% -- -- 2016-12-31
Tocqueville Opportunity 15000 0.04% -7000 -31.82% 2016-12-31
BNY Mellon EB DL Mkt Completion 18130 0.04% -1259 -6.49% 2016-12-31
Fidelity® Select Biotechnology Portfolio 1747667 6.10% -- -- 2015-09-30
Highland Long/Short Healthcare Fund 912430 3.20% 609242 200.90% 2015-06-30
Wellington Global Health Care Eq Port 437093 1.50% 82890 23.40% 2015-06-30
Franklin Biotechnology Discovery 304300 1.10% -- -- 2015-07-31
Fidelity Advisor® Biotechnology Fund 230804 0.80% -- -- 2015-09-30
Principal SmallCap Blend SP 191380 0.70% -- -- 2015-10-31
Fidelity® Series Growth Company Fund 137873 0.50% -- -- 2015-09-30
Principal SmallCap Fund 115300 0.40% -- -- 2015-10-31
Bridgeway Ultra Small Company Market 94437 0.30% 57437 155.20% 2015-09-30
TFS Market Neutral Fund 93570 0.30% 93570 -- 2015-07-31
AllianzGI Ultra Micro Cap Fund 83710 0.30% -- -- 2015-09-30
Fidelity Spartan® Extended Mkt Indx Fd 72909 0.20% 2138 3.00% 2015-09-30
Fidelity® Growth Company Fund 1816806 6.30% -19900 -1.10% 2015-09-30

Robert S. Epstein Robert S. Epstein is on the board of Illumina, Inc. and 4 other companies. In the past Dr. Epstein was President of Medco Research Institute LLC, President of Health Outcomes Research Europe SL, Chief Research & Development Officer at Medco Health Solutions, Inc. and President at International Society for Pharmacoeconomics & Outcomes Rsch. He received a doctorate and an undergraduate degree from the University of Michigan and a graduate degree from the University of Maryland.
Timothy P. Coughlin Mr. Timothy P. Coughlin, CPA, is an Independent Director at Peloton Therapeutics, Inc., an Independent Director at aTyr Pharma, Inc., an Independent Director at Retrophin, Inc. and an Independent Director at Fate Therapeutics, Inc. He is on the Board of Directors at Peloton Therapeutics, Inc., aTyr Pharma, Inc., Retrophin, Inc. and Fate Therapeutics, Inc. Mr. Coughlin was previously employed as a Vice President by Neurocrine Biosciences, Inc., a Vice President-Financial Services by Catholic Health Initiatives, and a Senior Manager-Health Sciences Practice by Ernst & Young LLP. He received his undergraduate degree from Temple University (Pennsylvania) and a graduate degree from San Diego State University.
William H. Rastetter Founder of Receptos LLC and Apoptos, Inc., William H. Rastetter is a businessperson who has been at the head of 11 different companies and presently is Chairman at Fate Therapeutics, Inc., Chairman for Neurocrine Biosciences, Inc. and Advisor at IIF Management Co. LLC. Dr. Rastetter is also on the board of 5 other companies. In the past Dr. Rastetter occupied the position of Chairman of Celgene Corp. Executive Chairman for Receptos LLC and Chairman & Chief Executive Officer of Apoptos, Inc. (both are subsidiaries of Celgene Corp.), Executive Chairman for Biogen, Inc. and Chairman & Chief Executive Officer at IDEC Pharmaceuticals Corp. (a subsidiary of Biogen, Inc.), Chairman of Illumina, Inc., Partner at Venrock Associates, Chairman of Cerulean Pharma, Inc., Director-Corporate Ventures at Genentech, Inc., Associate Professor at Massachusetts Institute of Technology and Faculty Member at Harvard University. William H. Rastetter received a doctorate and a graduate degree from Harvard University and an undergraduate degree from Massachusetts Institute of Technology.
John D. Mendlein Founder of Fate Therapeutics, Inc. and Homes for Sudan, John D. Mendlein is a businessperson who has been at the head of 5 different companies and is Executive Partners at Flagship Pioneering, Chairman at Chimeros Therapeutics and President-Corporate & Product Strategy at ModernaTX, Inc. He is also on the board of Biotechnology Innovation Organization, Fate Therapeutics, Inc. (former Chairman) and Homes for Sudan. In his past career Dr. Mendlein was Independent Director at aTyr Pharma, Inc., Attorney at Cooley LLP, President-Corporate & Product Strategy at Moderna, Inc., Chairman & Chief Executive Officer at Adnexus, Chairman & Chief Executive Officer at Affinium Pharmaceuticals Ltd., Scientist at GlaxoSmithKline Pharmaceuticals SA (Belgium) and Chief Knowledge Officer & General Counsel at Aurora Biosciences Corp. He received a doctorate from the University of California, Los Angeles, an undergraduate degree from the University of Miami and a graduate degree from the University of California, Hastings.
Amir H. Nashat Amir Nashat, Ph.D. has served on our board of directors since January 2016. He is a managing partner at Polaris Partners, a venture capital firm, where he has worked since 2002. Dr. Nashat also serves on the advisory board of the Partners Healthcare Innovation Fund. Dr. Nashat serves on the boards of directors of aTyr Pharma, Inc., Fate Therapeutics, Inc. and Selecta Biosciences, Inc., all biopharmaceutical companies. He previously served on the boards of directors of Bind Therapeutics, Inc. and Receptos, Inc., each a biopharmaceutical company. Dr. Nashat received a Ph.D. in chemical engineering from the Massachusetts Institute of Technology, and an M.S. and B.S. in materials science and mechanical engineering from the University of California, Berkeley. We believe Dr. Nashat is qualified to serve on our board of directors because of his experience on the boards of directors of other publicly-traded companies and his experience as an investor in biotechnology and life sciences companies.
J. Scott Wolchko J. Scott Wolchko founded Fate Therapeutics, Inc. Currently, Mr. Wolchko is President, Chief Executive Officer & Director at this company. He previously held the position of Chief Financial Officer at Bocada LLC, Member-Investment Banking Health Care Group at Morgan Stanley & Co. LLC and Senior Director-Corporate Development at drugstore.com LLC. He received a graduate degree from the University of Virginia and an undergraduate degree from the University of Vermont.
Mark J. Enyedy Mr. Mark J. Enyedy is on the Board of Directors at Keryx Biopharmaceuticals, Inc., ImmunoGen, Inc. and Fate Therapeutics, Inc. Mr. Enyedy was previously employed as Executive VP & Head-Corporate Development by Shire Plc, Chief Executive Officer & Director by Proteostasis Therapeutics, Inc., President-Transplant & Multiple Sclerosis by Genzyme Corp., and an Associate by Palmer & Dodge LLP. He received his undergraduate degree from Northeastern University and a graduate degree from Harvard Law School.
Daniel D. Shoemaker Currently, Daniel D. Shoemaker occupies the position of Chief Scientific Officer at Fate Therapeutics, Inc. He previously held the position of Chief Scientific Officer of ICX Biosystem, Chief Scientific Officer of Ghc Technologies, Inc. and Director-Target Discovery at Merck Research Laboratories. Daniel D. Shoemaker received a doctorate from Stanford University and an undergraduate degree from the University of California, Santa Barbara.
Michael Stewart Lee Mr. Michael S. Lee is a Managing Director at Redmile Group LLC. He is on the Board of Directors at Fate Therapeutics, Inc. and Gilda's Club New York City, Inc. He is a co-founder and portfolio manager of Redmile Group. Prior to Redmile, Mr. Lee worked as a biotechnology investor at Steeple Capital, and before that at Welch Capital Partners and Prudential Equity Group. He holds a B.S. in Molecular and Cellular Biology from the University of Arizona.
Jim Beitel Jim Beitel is Senior Vice President-Corporate Development of Fate Therapeutics, Inc. Mr. Beitel previously held the position of Director & Director-Business Development at Zacharon Pharmaceuticals, Inc. and Vice President-Corporate Development & Operations at Avanir Pharmaceuticals, Inc. He received an MBA from Harvard University and an undergraduate degree from the University of Kansas.
Cindy R. Tahl Presently, Cindy R. Tahl holds the position of Secretary & General Counsel at Fate Therapeutics, Inc. She is also Member of New York State Bar Association. In the past she was Associate of Wilson Sonsini Goodrich & Rosati PC, Associate of Kenyon & Kenyon LLP and Member of California State Bar Association. She received an undergraduate degree from the University of California San Diego and a graduate degree from Boston College Law School.
Timothy P. Coughlin Mr. Timothy P. Coughlin, CPA, is an Independent Director at Peloton Therapeutics, Inc., an Independent Director at aTyr Pharma, Inc., an Independent Director at Retrophin, Inc. and an Independent Director at Fate Therapeutics, Inc. He is on the Board of Directors at Peloton Therapeutics, Inc., aTyr Pharma, Inc., Retrophin, Inc. and Fate Therapeutics, Inc. Mr. Coughlin was previously employed as a Vice President by Neurocrine Biosciences, Inc., a Vice President-Financial Services by Catholic Health Initiatives, and a Senior Manager-Health Sciences Practice by Ernst & Young LLP. He received his undergraduate degree from Temple University (Pennsylvania) and a graduate degree from San Diego State University.
Robert S. Epstein Robert S. Epstein is on the board of Illumina, Inc. and 4 other companies. In the past Dr. Epstein was President of Medco Research Institute LLC, President of Health Outcomes Research Europe SL, Chief Research & Development Officer at Medco Health Solutions, Inc. and President at International Society for Pharmacoeconomics & Outcomes Rsch. He received a doctorate and an undergraduate degree from the University of Michigan and a graduate degree from the University of Maryland.
Robert S. Epstein Robert S. Epstein is on the board of Illumina, Inc. and 4 other companies. In the past Dr. Epstein was President of Medco Research Institute LLC, President of Health Outcomes Research Europe SL, Chief Research & Development Officer at Medco Health Solutions, Inc. and President at International Society for Pharmacoeconomics & Outcomes Rsch. He received a doctorate and an undergraduate degree from the University of Michigan and a graduate degree from the University of Maryland.
Karin Jooss Karin Jooss is Chief Scientific Officer & EVP-Research at Gritstone Oncology, Inc. Dr. Jooss is also on the board of Fate Therapeutics, Inc. In her past career she held the position of Head-Cancer Immunotherapeutics at Pfizer Inc. and Vice President-Research at Cell Genesys, Inc. Dr. Jooss received a doctorate from Philipps University of Marburg.
Robert S. Epstein Robert S. Epstein is on the board of Illumina, Inc. and 4 other companies. Dr. Epstein previously was President at Medco Research Institute LLC, President at Health Outcomes Research Europe SL, Chief Research & Development Officer at Medco Health Solutions, Inc. and President at International Society for Pharmacoeconomics & Outcomes Rsch. Robert S. Epstein received a doctorate and an undergraduate degree from the University of Michigan and a graduate degree from the University of Maryland.
Shefali Agarwal Dr. Shefali Agarwal, MD, is a Chief Medical Officer at Epizyme, Inc. She is on the Board of Directors at Fate Therapeutics, Inc. Dr. Agarwal was previously employed as a Chief Medical Officer by SQZ Biotechnologies Co. She received her graduate degree from The Johns Hopkins University, a graduate degree from Merrick School of Business and a doctorate degree from Karnataka University.
Bahram Valamehr Bahram Valamehr is Chief Development Officer for Fate Therapeutics, Inc. Mr. Valamehr received a doctorate and an undergraduate degree from the University of California Los Angeles Graduate School and an MBA from Pepperdine University.
Wen Bo Wang Wen Bo Wang is on the board of Standards Coordinating Body and Senior Vice President-Technical Operations at Fate Therapeutics, Inc. In his past career Dr. Wang occupied the position of Senior Vice President-Cell Therapy at Cellular Dynamics International, Inc. and Associate Scientific Director at ViaCell, Inc. Dr. Wang received an undergraduate degree from Ocean University of China and a doctorate from Newcastle University.
Sarah Cooley Sarah Cooley is Senior Vice President-Clinical Translation at Fate Therapeutics, Inc. Dr. Cooley received an undergraduate degree from Cornell University, a graduate degree from the University of Minnesota Medical School and a graduate degree from the University of Minnesota.
Yu Waye Chu Yu Waye Chu occupies the position of Vice President-Clinical Development at Fate Therapeutics, Inc. Dr. Chu received an undergraduate degree from Princeton University and a doctorate from the University of Rochester School of Medicine & Dentistry.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐